

### Krazati(adagrasib) Prior Authorization Request Form Caterpillar Prescription Drug Benefit



Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: \_\_\_\_\_

MEMBER'S FIRST NAME: \_\_\_\_\_

**Instructions:** Please fill out all applicable sections completely and legibly. Attach any additional documentation that is important for the review (e.g., chart notes or lab data, to support the authorization request). Information contained in this form is Protected Health Information under HIPAA.

MEMBER INFORMATION		
LAST NAME:	FIRST NAME:	
PHONE NUMBER:	DATE OF BIRTH:	
STREET ADDRESS:		
CITY:	STATE: ZIP CODE:	
PATIENT INSURANCE ID NUMBER:		
MALE FEMALE HEIGHT (IN/CM):	WEIGHT (LB/KG): ALLERGIES:	

IF YOU ARE NOT THE PATIENT OR THE PRESCRIBER, YOU WILL NEED TO SUBMIT A PHI DISCLOSURE AUTHORIZATION FORM WITH THIS REQUEST WHICH CAN BE FOUND AT THE FOLLOWING LINK: <u>https://magellanrx.com/member/external/commercial/common/doc/en-us/phi\_disclosure\_authorization.pdf</u>

#### PATIENT'S AUTHORIZED REPRESENTATIVE (IF APPLICABLE): \_\_\_\_\_\_

AUTHORIZED REPRESENTATIVE'S PHONE NUMBER:

PRESCRIBER INFORMATION				
LAST NAME:	FIRST NAME:			
PRESCRIBER SPECIALTY:	EMAIL ADDRESS:			
NPI NUMBER:	DEA NUMBER:			
PHONE NUMBER:	FAX NUMBER:			
STREET ADDRESS:				
CITY:	STATE: ZIP CODE:			
REQUESTOR (if different than prescriber):	OFFICE CONTACT PERSON:			

MEDICATION OR MEDICAL DISPENSING INFORMATION					
MEDICATION NAME:					
DOSE/STRENGTH:	FREQUENCY:	LENGTH OF THERAPY/REFILLS:	QUANTITY:		
NEW THERAPY	RENEWAL	IF RENEWAL: DATE THERAPY INITIATED:			
DURATION OF THERAPY (SPECIFIC DATES):					

Continued on next page

© 2017 – 2022 by Magellan Rx Management, LLC. All Rights Reserved. Magellan Rx Management – Commercial Clients. Revision Date: 4.15.2024 CAT0295





## Krazati(adagrasib) **Prior Authorization Request Form**



Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME:	MEMBER'S FIRST NAME:		
1. HAS THE PATIENT TRIED ANY OTHE	ER MEDICATIONS FOR THIS CONDITION?	YES (if yes, complete below) NO	
MEDICATION/THERAPY (SPECIFY DRUG NAME AND DOSAGE):	<b>DURATION OF THERAPY</b> (SPECIFY DATES):	RESPONSE/REASON FOR FAILURE/ALLERGY:	
2. LIST DIAGNOSES:		ICD-10:	
<ul> <li>Non Small Cell Lunc Cancer(NSCLC)</li> </ul>			
Other diagnosis:ICD-10ICD-10			
<b>3. REQUIRED CLINICAL INFORMATIO</b> PRIOR AUTHORIZATION.	N: PLEASE PROVIDE ALL RELEVANT CLIN	NICAL INFORMATION TO SUPPORT A	
Clinical Information: Is this drug being prescribed to this trial?  Yes  No <u>Initial Request</u> : Is prescriber an oncologist or hemat	patient as part of a treatment regimen cologist?  u Yes  u No	specified within a sponsored clinical	
Is patient's diagnosis locally advance documentation.	d or metastatic non-small cell lung canc	er (NSCLC)?   Yes  No Please provide	
Does patient have an ECOG score of	at least 2?   Yes  No Please provide	documentation.	
Does patient have the KRAS G12C-m	nutation?      Yes   No Please provide definition of the second definit	ocumentation.	
Renewal Request:	eatment for their NSCLC?  • Yes  • No F • a positive clinical response?  • Yes  •		
Are there any other comments, diag physician feels is important to this re	noses, symptoms, medications tried or fa eview?	ailed, and/or any other information the	
Please note: Not all drugs/diagnosis a information is received.	are covered on all plans. This request ma	ay be denied unless all required	
the Health Plan, insurer, Medical Gro	on provided is true and accurate to the b up or its designees may perform a routin ccuracy of the information reported on th	e audit and request the medical	
Prescriber Signature or Electronic I.D	. Verification:	Date:	
© 2017 – 2022 by Magellan Rx Management, L Magellan Rx Management – Commercial Client CAT0295	-		





# Krazati(adagrasib) **Prior Authorization Request Form**



**Caterpillar Prescription Drug Benefit** Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: \_\_\_\_\_\_ MEMBER'S FIRST NAME: \_\_\_\_\_

CONFIDENTIALITY NOTICE: The documents accompanying this transmission contain confidential health information that is legally privileged. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly prohibited. If you have received this information in error, please notify the sender immediately (via return FAX) and arrange for the return or destruction of these documents.

### FAX THIS FORM TO: 800-424-7640

MAIL REQUESTS TO: Magellan Rx Management Prior Authorization Program Attn:CP-4201 P.O.Box 64811 St. Paul, MN 55164-0811

Phone: 877-228-7909



